Want to see AU:TLX full AI Analyst Report?
TLX Stock Chart & Stats
AU$14.66
-AU$0.38(-2.59%)
At close: 4:00 PM EDT
AU$14.66
-AU$0.38(-2.59%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$21.05
Previous CloseN/A
Volume2.26M
Average Volume (3M)1.87M
Market Cap
AU$4.83B
Enterprise ValueAU$4.28K
Total Cash (Recent Filing)AU$212.74M
Total Debt (Recent Filing)AU$699.77M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 20, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding339,784,300
10 Day Avg. Volume1,472,861
30 Day Avg. Volume1,873,147
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.27Price Target Upside72.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$982.59M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Scaling And FY26 GuidanceMulti-year, double-digit top-line growth plus explicit FY2026 guidance indicate durable commercial demand and a widening revenue base. That scale supports continued reinvestment, funds manufacturing and R&D expansions, and reduces reliance on one-off milestones for near-term cash generation.
High‑margin Precision Medicine FranchiseA concentrated, high-margin diagnostic/therapeutic engine provides recurring, cash-generative revenues that underpin company economics. Durable margin contribution from Precision Medicine supports self‑funding of R&D, helps absorb commercialization costs, and stabilizes operating leverage as scale increases.
In‑house Manufacturing And RLS ContributionOwnership of manufacturing and expanded supply capability strengthens supply resilience and margin capture over time. Positive EBITDA from RLS and full-year integration reduce third‑party risk, enable volume scalability for radiopharmaceuticals, and support consistent commercial supply as international launches progress.
Bears Say
Rising LeverageA marked step-up in debt reduces financial flexibility and increases fixed obligations if earnings fluctuate. For a company still investing aggressively in R&D and commercialization, higher leverage raises refinancing and covenant risk and constrains discretionary allocation during execution delays.
Weakening Operating Cash Flow And FCFThe reversal to negative OCF/FCF signals weaker cash conversion and higher working capital or spending needs. Persistent negative cash flow amid elevated R&D and capex increases the likelihood of external financing, pressuring liquidity and potentially diluting strategic optionality over the medium term.
Regulatory Execution Risk For TherapeuticsRequired resubmissions delay potential therapeutic launches and associated revenue, extending the timeline to monetize late‑stage assets. Regulatory uncertainty increases ongoing R&D and compliance costs and creates binary outcomes that materially affect long‑term revenue diversification and profitability.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$21.05 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$4.83B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 17 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.057 by -AU$0.074.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,784,300 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.057. Following the earnings report the stock price went up 14.239%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.27 (72.35% Upside)
AU$25.27 (72.35% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $794.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX Stock 12 Month Forecast
Average Price Target
AU$25.27
▲(72.35% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―